EQT offers QIAGEN shareholders a 40% premium, but can its €10.8bn diagnostics bet unlock faster growth?
EQT agrees a €10.8 billion takeover of QIAGEN at €46.50 per share. Diagnostics growth, financing and shareholder approval remain key.
Medical Devices & Diagnostics
Pharma & Biotech
Why Recordati’s $12.4bn takeover bid could reshape Italy’s listed pharma landscape
Recordati’s $12.4bn buyout bid tests whether rare disease growth can justify one of Europe’s biggest pharma take-private deals.